Skip to main content
Erschienen in: Lung 3/2018

17.03.2018 | LUNG CANCER

Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer

verfasst von: Jacob Y. Shin, Ja Kyoung Yoon, Gaurav Marwaha

Erschienen in: Lung | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to assess temporal trends in population-based treatment and survival rates in patients with early-stage non-small cell lung cancer (NSCLC).

Methods

Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Chi-square test, Kaplan–Meier method, and Cox regression models were employed in SPSS 23.0.

Results

Fifty-seven thousand and eighty-eight NSCLC patients with early-stage disease from 1988 to 2014 were identified. 6409 (11.2%) were diagnosed in 1988–1994, 5800 (10.2%) 1995–1999, 13,031 (22.8%) 2000–2004, 15,786 (27.7%) 2005–2009, and 16,062 (28.1%) 2010–2014. We observed a significant increase in the proportion of older patients, adenocarcinoma histology, and rate of wedge resection over the study period. The five-year overall survival (OS) for the entire cohort was 63.3%. Those undergoing resection without adjuvant therapy had the highest outcomes. Lobectomy was associated with better outcomes compared to wedge resection or pneumonectomy. A significant difference in five-year OS by year of diagnosis (1988–1994: 58.8% vs. 1995–1999: 60.6% vs. 2000–2004: 63.2% vs. 2005–2009: 66.1%; p < 0.001) was observed. This significant OS difference was also observed regardless of age, surgery type, and T stage, but also only in those with adenocarcinoma. On multivariable analysis, year of diagnosis, age, gender, race, treatment and surgery type, histology, T stage, and tumor grade remained independent prognostic factors for OS.

Conclusions

Overall survival for early-stage NSCLC has significantly improved over the recent decades despite an increasing proportion of older patients and those undergoing sublobar resection or SBRT. This finding may be limited to those with adenocarcinoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Church TR, Black WC, Aberle DR et al (2013) Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 368:1980–1991CrossRefPubMed Church TR, Black WC, Aberle DR et al (2013) Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 368:1980–1991CrossRefPubMed
3.
Zurück zum Zitat Flores RM, Park BJ, Dycoco J et al (2009) Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg 138:11–18CrossRefPubMed Flores RM, Park BJ, Dycoco J et al (2009) Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg 138:11–18CrossRefPubMed
4.
Zurück zum Zitat Nakamura H, Kawasaki N, Taguchi M et al (2005) Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. Br J Cancer 92:1033–1037CrossRefPubMedPubMedCentral Nakamura H, Kawasaki N, Taguchi M et al (2005) Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. Br J Cancer 92:1033–1037CrossRefPubMedPubMedCentral
5.
7.
Zurück zum Zitat Detterbeck FC, Chansky K, Groome P et al (2016) The IASLC lung cancer staging project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (eighth) edition of the TNM classification of lung cancer. J Thorac Oncol 11:1433–1446CrossRefPubMed Detterbeck FC, Chansky K, Groome P et al (2016) The IASLC lung cancer staging project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (eighth) edition of the TNM classification of lung cancer. J Thorac Oncol 11:1433–1446CrossRefPubMed
8.
Zurück zum Zitat Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622 discussion 622–613.CrossRefPubMed Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615–622 discussion 622–613.CrossRefPubMed
9.
Zurück zum Zitat Keenan RJ, Landreneau RJ, Maley RH Jr., et al (2004) Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg 78:228–233; discussion 228–233CrossRefPubMed Keenan RJ, Landreneau RJ, Maley RH Jr., et al (2004) Segmental resection spares pulmonary function in patients with stage I lung cancer. Ann Thorac Surg 78:228–233; discussion 228–233CrossRefPubMed
10.
Zurück zum Zitat Kilic A, Schuchert MJ, Pettiford BL et al (2009) Anatomic segmentectomy for stage I non-small cell lung cancer in the elderly. Ann Thorac Surg 87:1662–1666; discussion 1667–1668CrossRefPubMed Kilic A, Schuchert MJ, Pettiford BL et al (2009) Anatomic segmentectomy for stage I non-small cell lung cancer in the elderly. Ann Thorac Surg 87:1662–1666; discussion 1667–1668CrossRefPubMed
11.
Zurück zum Zitat Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28:928–935CrossRefPubMed Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28:928–935CrossRefPubMed
12.
Zurück zum Zitat Raz DJ, Zell JA, Ou SH et al (2007) Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 132:193–199CrossRefPubMed Raz DJ, Zell JA, Ou SH et al (2007) Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 132:193–199CrossRefPubMed
13.
Zurück zum Zitat Wisnivesky JP, Bonomi M, Henschke C et al (2005) Radiation therapy for the treatment of unresected stage I–II non-small cell lung cancer. Chest 128:1461–1467CrossRefPubMed Wisnivesky JP, Bonomi M, Henschke C et al (2005) Radiation therapy for the treatment of unresected stage I–II non-small cell lung cancer. Chest 128:1461–1467CrossRefPubMed
14.
Zurück zum Zitat Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637CrossRefPubMedPubMedCentral Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kenfield SA, Wei EK, Stampfer MJ et al (2008) Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 17:198–204CrossRefPubMedPubMedCentral Kenfield SA, Wei EK, Stampfer MJ et al (2008) Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 17:198–204CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Holford TR, Levy DT, McKay LA et al (2014) Patterns of birth cohort-specific smoking histories, 1965–2009. Am J Prev Med 46:e31–e37CrossRef Holford TR, Levy DT, McKay LA et al (2014) Patterns of birth cohort-specific smoking histories, 1965–2009. Am J Prev Med 46:e31–e37CrossRef
17.
Zurück zum Zitat Meza R, Meernik C, Jeon J et al (2015) Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLoS ONE 10:e0121323CrossRefPubMedPubMedCentral Meza R, Meernik C, Jeon J et al (2015) Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLoS ONE 10:e0121323CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Patel JD, Hensing TA, Rademaker A et al (2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27:3284–3289CrossRefPubMed Patel JD, Hensing TA, Rademaker A et al (2009) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27:3284–3289CrossRefPubMed
19.
Zurück zum Zitat Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMed Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMed
20.
Zurück zum Zitat Hoyert DL (2012) 75 Years of Mortality in the United States, 1935–2010. Age 88:1400 Hoyert DL (2012) 75 Years of Mortality in the United States, 1935–2010. Age 88:1400
21.
Zurück zum Zitat Gridelli C, Langer C, Maione P et al (2007) Lung cancer in the elderly. J Clin Oncol 25:1898–1907CrossRefPubMed Gridelli C, Langer C, Maione P et al (2007) Lung cancer in the elderly. J Clin Oncol 25:1898–1907CrossRefPubMed
22.
Zurück zum Zitat Mery CM, Pappas AN, Bueno R et al (2005) Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest 128:237–245CrossRefPubMed Mery CM, Pappas AN, Bueno R et al (2005) Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest 128:237–245CrossRefPubMed
23.
Zurück zum Zitat Palma D, Visser O, Lagerwaard FJ et al (2010) Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28:5153–5159CrossRefPubMed Palma D, Visser O, Lagerwaard FJ et al (2010) Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28:5153–5159CrossRefPubMed
24.
Zurück zum Zitat Fernandez FG, Furnary AP, Kosinski AS et al (2016) Longitudinal follow-up of lung cancer resection from the society of thoracic surgeons general thoracic surgery database in patients 65 years and older. Ann Thorac Surg 101:2067–2076CrossRefPubMed Fernandez FG, Furnary AP, Kosinski AS et al (2016) Longitudinal follow-up of lung cancer resection from the society of thoracic surgeons general thoracic surgery database in patients 65 years and older. Ann Thorac Surg 101:2067–2076CrossRefPubMed
25.
Zurück zum Zitat Eguchi T, Bains S, Lee MC et al (2017) Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung cancer: a competing risks analysis. J Clin Oncol 35:281–290CrossRefPubMed Eguchi T, Bains S, Lee MC et al (2017) Impact of increasing age on cause-specific mortality and morbidity in patients with stage I non-small-cell lung cancer: a competing risks analysis. J Clin Oncol 35:281–290CrossRefPubMed
26.
Zurück zum Zitat Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552–3559CrossRefPubMed Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552–3559CrossRefPubMed
27.
Zurück zum Zitat Strauss GM, Herndon JE 2nd, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043–5051CrossRefPubMedPubMedCentral Strauss GM, Herndon JE 2nd, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043–5051CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Guidelines Version NCCN. 2.2018. Non-small cell lung cancer. National Comprehensive Cancer Network. December 19, 2017. Accessed January 13, 2018 Guidelines Version NCCN. 2.2018. Non-small cell lung cancer. National Comprehensive Cancer Network. December 19, 2017. Accessed January 13, 2018
29.
Zurück zum Zitat Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604–1608CrossRefPubMed Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604–1608CrossRefPubMed
30.
Zurück zum Zitat Dinan MA, Curtis LH, Carpenter WR et al (2012) Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998–2003. J Clin Oncol 30:2725–2730CrossRefPubMed Dinan MA, Curtis LH, Carpenter WR et al (2012) Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998–2003. J Clin Oncol 30:2725–2730CrossRefPubMed
31.
Zurück zum Zitat Navani N, Nankivell M, Lawrence DR et al (2015) Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med 3:282–289CrossRefPubMedPubMedCentral Navani N, Nankivell M, Lawrence DR et al (2015) Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. Lancet Respir Med 3:282–289CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Bradley J, Thorstad WL, Mutic S et al (2004) Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:78–86CrossRefPubMed Bradley J, Thorstad WL, Mutic S et al (2004) Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:78–86CrossRefPubMed
33.
Zurück zum Zitat Kawaguchi T, Takada M, Kubo A et al (2010) Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5:620–630CrossRefPubMed Kawaguchi T, Takada M, Kubo A et al (2010) Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 5:620–630CrossRefPubMed
34.
Zurück zum Zitat Battafarano RJ, Piccirillo JF, Meyers BF et al (2002) Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 123:280–287CrossRefPubMed Battafarano RJ, Piccirillo JF, Meyers BF et al (2002) Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 123:280–287CrossRefPubMed
35.
Zurück zum Zitat Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRefPubMed Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRefPubMed
36.
Zurück zum Zitat Brugger W, Triller N, Blasinska-Morawiec M et al (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113–4120CrossRefPubMed Brugger W, Triller N, Blasinska-Morawiec M et al (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29:4113–4120CrossRefPubMed
Metadaten
Titel
Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer
verfasst von
Jacob Y. Shin
Ja Kyoung Yoon
Gaurav Marwaha
Publikationsdatum
17.03.2018
Verlag
Springer US
Erschienen in
Lung / Ausgabe 3/2018
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-018-0110-1

Weitere Artikel der Ausgabe 3/2018

Lung 3/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.